Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome

Sustained correction of associative learning deficits after brief, early treatment in a rat model of Fragile X Syndrome

(2019) Antonis Asiminas et al.   Science Translational Medicine

Effects of the presence and absence of amino acids on translation, signaling and long‐term depression in hippocampal slices from Fmr1 knockout mice

(2019) Spencer K. Cooke et al.   JOURNAL OF NEUROCHEMISTRY

Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia

(2018) Florence F. Wagner et al.   Science Translational Medicine

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

(2018) Sébastien Jacquemont et al.   HUMAN MOLECULAR GENETICS

Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety

(2017) Tori L. Schaefer et al.   Journal of Neurodevelopmental Disorders

Metformin ameliorates core deficits in a mouse model of fragile X syndrome

(2017) Ilse Gantois et al.   NATURE MEDICINE

Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome

(2017) Sophie R. Thomson et al.   NEURON

Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects

(2016) Florence F. Wagner et al.   ACS Chemical Biology

Lithium treatment and cancer incidence in bipolar disorder

(2016) Lina Martinsson et al.   BIPOLAR DISORDERS

Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study

(2016) Ru-Yu Huang et al.   BRITISH JOURNAL OF PSYCHIATRY

Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome

(2016) Marta Pardo et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice

(2016) W. Guo et al.   JOURNAL OF NEUROSCIENCE

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

(2016) Elizabeth Berry-Kravis et al.   Science Translational Medicine

Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models

(2016) Catherine H. Choi et al.   Frontiers in Behavioral Neuroscience

APP Causes Hyperexcitability in Fragile X Mice

(2016) Cara J. Westmark et al.   Frontiers in Molecular Neuroscience

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome

(2015) Sebastian H Scharf et al.   CURRENT OPINION IN PHARMACOLOGY

Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS

(2015) Sally M. Till et al.   HUMAN MOLECULAR GENETICS

R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome

(2015) Mei Qin et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Fragile X disappointments upset autism ambitions

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Dysregulation and restoration of translational homeostasis in fragile X syndrome

(2015) Joel D. Richter et al.   NATURE REVIEWS NEUROSCIENCE

Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test

(2015) C.E.F. de Esch et al.   NEUROBIOLOGY OF DISEASE

Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents

(2015) Jerri M. Rook et al.   NEURON

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

(2015) Eleonore Beurel et al.   PHARMACOLOGY & THERAPEUTICS

Rapid alteration of protein phosphorylation during postmortem: implication in the study of protein phosphorylation

(2015) Yifan Wang et al.   Scientific Reports

Glycogen Synthase Kinase-3 as a Therapeutic Target for Cognitive Dysfunction in Neuropsychiatric Disorders

(2014) Olivia O’Leary et al.   CNS DRUGS

Preliminary Investigation of Lithium for Mood Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder

(2014) Matthew Siegel et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Preclinical Toxicity of AZD7969

(2014) A. P. Hall et al.   TOXICOLOGIC PATHOLOGY

Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome

(2013) M. K. King et al.   GENES BRAIN AND BEHAVIOR

Activation of the Wnt Pathway through AR79, a GSK3  Inhibitor, Promotes Prostate Cancer Growth in Soft Tissue and Bone

(2013) Y. Jiang et al.   MOLECULAR CANCER RESEARCH

Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology

(2013) Tsuyoshi Udagawa et al.   NATURE MEDICINE

Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome

(2013) Emily K. Osterweil et al.   NEURON

The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)

(2012) Asha L. Bhakar et al.   Annual Review of Neuroscience

Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome

(2012) Jennifer A Ronesi et al.   NATURE NEUROSCIENCE

Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice

(2012) Aubin Michalon et al.   NEURON

Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant

(2012) Andreea S. Pop et al.   PSYCHOPHARMACOLOGY

A pivotal role of GSK-3 in synaptic plasticity

(2012) Clarrisa A. Bradley et al.   Frontiers in Molecular Neuroscience

FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism

(2011) Jennifer C. Darnell et al.   CELL

What Can We Learn about Autism from Studying Fragile X Syndrome?

(2011) Dejan B. Budimirovic et al.   DEVELOPMENTAL NEUROSCIENCE

Inhibition of GSK3  improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome

(2011) W. Guo et al.   HUMAN MOLECULAR GENETICS

Altered Neocortical Rhythmic Activity States in Fmr1 KO Mice Are Due to Enhanced mGluR5 Signaling and Involve Changes in Excitatory Circuitry

(2011) S. A. Hays et al.   JOURNAL OF NEUROSCIENCE

Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome

(2011) Zhong-Hua Liu et al.   NEUROBIOLOGY OF DISEASE

AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice

(2011) Jen Q Pan et al.   NEUROPSYCHOPHARMACOLOGY

Glycogen Synthase Kinase-3: A Promising Therapeutic Target for Fragile X Syndrome

(2011) Marjelo A. Mines et al.   Frontiers in Molecular Neuroscience

GSK-3: Functional Insights from Cell Biology and Animal Models

(2011) Oksana Kaidanovich-Beilin et al.   Frontiers in Molecular Neuroscience

Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome

(2010) Dilja D. Krueger et al.   Annual Review of Medicine

Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

(2010) Catherine H. Choi et al.   BRAIN RESEARCH

Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome

(2010) Zhong-Hua Liu et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome

(2010) E. K. Osterweil et al.   JOURNAL OF NEUROSCIENCE

Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndrome

(2009) Christopher J. Yuskaitis et al.   BIOCHEMICAL PHARMACOLOGY

Rapid Neocortical Dynamics: Cellular and Network Mechanisms

(2009) Bilal Haider et al.   NEURON

A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases

(2009) Stéphane Peineau et al.   Molecular Brain

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice

(2009) Oksana Kaidanovich-Beilin et al.   Molecular Brain

Co-occurring conditions associated withFMR1gene variations: Findings from a national parent survey

(2008) Donald B. Bailey et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome

(2008) Elizabeth Berry-Kravis et al.   JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS

Imbalance of Neocortical Excitation and Inhibition and Altered UP States Reflect Network Hyperexcitability in the Mouse Model of Fragile X Syndrome

(2008) Jay R. Gibson et al.   JOURNAL OF NEUROPHYSIOLOGY

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome

(2008) Gül Dölen et al.   JOURNAL OF PHYSIOLOGY-LONDON

Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila

(2008) Shuang Chang et al.   Nature Chemical Biology

Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential

(2008) Wenzhong William Min et al.   NEUROPHARMACOLOGY

Advances in the Treatment of Fragile X Syndrome

(2008) R. J. Hagerman et al.   PEDIATRICS